NRx Pharmaceuticals announced that has received confirmation from Nasdaq that they have demonstrated compliance with the Nasdaq bid price requirement in Listing Rule 5550(a)(2) and has determined to continue the listing of the company’s securities on The Nasdaq Stock Market and is closing this matter.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRXP:
- NRx Pharmaceuticals announces new data on NRX-101
- NRx Pharmaceuticals develops new proprietary formulation of HTX-100
- NRx Pharmaceuticals achieves data-lock of Phase 2b/3 trial of NRX-101
- NRX Pharmaceuticals trading halted, news pending
- NRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
